Patents by Inventor Oh Young Bang

Oh Young Bang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200129433
    Abstract: The present invention relates to stem cell-derived microvesicles with enhanced efficacy, a use thereof, and a method for enhancing efficacy, and more particularly, to a use of stem cell-derived microvesicles with an enhanced expression level of microRNAs for the prevention or treatment of stroke, and a method for promoting the production of microRNAs of stem cell-derived microvesicles and enhancing efficacy, and a method for promoting the production of stem cell-derived microvesicles and microRNAs within the microvesicles and enhancing the efficacy of stem cells and microvesicles thereof by 3-dimensionally culturing or ischemically stimulating stem cells.
    Type: Application
    Filed: October 14, 2019
    Publication date: April 30, 2020
    Inventors: Oh Young BANG, Eun Hee KIM, Jae Min CHA
  • Patent number: 10406180
    Abstract: The present invention relates to a composition including stem cell-derived microvesicles as an active ingredient for promoting neurogenesis. The stem cell-derived microvesicles according to the present invention can promote neurogenesis and migration of nerves and also promote angiogenesis in vascular endothelial cells, and thus can be usefully used in treatment of neurological damage.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: September 10, 2019
    Assignee: Samsung Life Public Welfare Foundation
    Inventors: Oh Young Bang, Gyeong Joon Moon, Yeon Hee Cho, Suk Jae Kim, Dong Hee Kim, Ji Hee Sung
  • Publication number: 20190144830
    Abstract: Provided are a method for producing stem cell-derived extracellular vesicles by using a three-dimensional cell culture process, use of three-dimensional cell aggregates of stem cells in producing extracellular vesicles, a culture of three-dimensional cell aggregates of stem cells comprising a high concentration of extracellular vesicles, and a pharmaceutical composition comprising the culture.
    Type: Application
    Filed: April 29, 2016
    Publication date: May 16, 2019
    Inventors: Jae Min CHA, Oh Young BANG, Gyeong Joon MOON, Eun Kyoung SHIN
  • Publication number: 20190038752
    Abstract: The present invention relates to a composition for topically delivering SDF-1 into the brain, in which the composition comprises a dual ionic pH-sensitive copolymer and a nerve regeneration and protective factor. In the present invention, when a dual ionic pH-sensitive copolymer containing SDF-1 as a nerve regeneration and protective factor is applied to a patient suffering from ischemic stroke as a drug carrier, it induces the effective delivery of the treatment factor to a topical lesion site, and moreover, the risk factors for adverse effects may be cancelled out, so that it can be effectively used as a novel therapeutic agent for ischemic brain diseases.
    Type: Application
    Filed: August 7, 2018
    Publication date: February 7, 2019
    Inventors: Oh Young Bang, Dong Hee Kim, Gyeong Joon Moon, Hyeon Ho Kim, Doo Sung Lee, Young Kyu Seo
  • Patent number: 10072247
    Abstract: The present invention relates to a composition comprising an ischemic serum for promoting the activation of a stem cell, to a method for promoting the activation of a stem cell and to a stem cell, the activation of which is promoted by the composition or the method. The ischemic serum according to the present invention may stimulate the stem cell to facilitate the secretion of a growth factor, improve survival rate, improve mobility to an injured part, improve proliferation rate and maintain characteristics of the stem cell, thus promoting an activation of the stem cell such that the stem cell becomes suitable for transplantation of the stem cell to a patient having a brain injury.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: September 11, 2018
    Assignee: Samsung Life Public Welfare Foundation
    Inventors: Oh Young Bang, Gyeong Joon Moon, Yeon Hee Cho, Suk Jae Kim, Dong Hee Kim, Soo Kyung Ryoo, Ji Hyun Lee, Ji Yoon Nam, Ji Hee Sung
  • Publication number: 20180030535
    Abstract: Provided are a biomarker composition for the diagnosis of moyamoya disease, including caveolin-1, a kit for the diagnosis of moyamoya disease, a method of providing information for moyamoya disease diagnosis, and a method of screening a moyamoya disease therapeutic agent. According to the present disclosure, specific treatment for moyamoya disease is possible by distinguishing the disease from atherosclerosis, which is a similar cerebrovascular stenosis disease, and thus unnecessary factors or risk factors that may be accompanied by side effects may be avoided and, therefore, may be applied to effective MMD therapies.
    Type: Application
    Filed: July 25, 2017
    Publication date: February 1, 2018
    Inventors: Oh Young BANG, Gyeong Joon MOON, Jong-Won CHUNG, Mi Jeong OH, Dong Hee KIM, Soo Yoon KIM, Yeon Hee CHO
  • Publication number: 20170368103
    Abstract: The present invention relates to a composition including stem cell-derived microvesicles as an active ingredient for promoting neurogenesis. The stem cell-derived microvesicles according to the present invention can promote neurogenesis and migration of nerves and also promote angiogenesis in vascular endothelial cells, and thus can be usefully used in treatment of neurological damage.
    Type: Application
    Filed: July 14, 2017
    Publication date: December 28, 2017
    Inventors: Oh Young Bang, Gyeong Joon Moon, Yeon Hee Cho, Suk Jae Kim, Dong Hee Kim, Ji Hee Sung
  • Publication number: 20170274081
    Abstract: The present invention relates to a composition for topically delivering SDF-1 into the brain, in which the composition comprises a dual ionic pH-sensitive copolymer and a nerve regeneration and protective factor. In the present invention, when a dual ionic pH-sensitive copolymer containing SDF-1 as a nerve regeneration and protective factor is applied to a patient suffering from ischemic stroke as a drug carrier, it induces the effective delivery of the treatment factor to a topical lesion site, and moreover, the risk factors for adverse effects may be cancelled out, so that it can be effectively used as a novel therapeutic agent for ischemic brain diseases.
    Type: Application
    Filed: March 24, 2017
    Publication date: September 28, 2017
    Applicants: Samsung Life Public Welfare Foundation, Research & Business Foundation Sungkyunkwan University
    Inventors: Oh Young Bang, Dong Hee Kim, Gyeong Joon Moon, Hyeon Ho Kim, Doo Sung Lee, Young Kyu Seo
  • Publication number: 20160125597
    Abstract: The present invention relates to a novel magnetic resonance image technique for imaging collateral circulation in a human body. In the present invention, source data of a dynamic susceptibility contrast enhancement perfusion-weighted image (DSC-PWI) is subjected to an image-post-processing and an image obtained through the image-post-processing is then compared with an image obtained by digital subtraction angiography (DSA), thereby imaging the collateral circulation. The method according to the present invention can non-invasively, rapidly and easily visualize and evaluate the collateral circulation. Therefore, the method can provide information, which is important for understanding, treatment strategy determination and outcome prediction of a disease generated due to angiostenosis or occlusion.
    Type: Application
    Filed: April 17, 2014
    Publication date: May 5, 2016
    Inventors: Oh Young BANG, Suk Jae KIM, Jeong Pyo SON
  • Publication number: 20150337264
    Abstract: The present invention relates to a composition comprising an ischemic serum for promoting the activation of a stem cell, to a method for promoting the activation of a stem cell and to a stem cell, the activation of which is promoted by the composition or the method. The ischemic serum according to the present invention may stimulate the stem cell to facilitate the secretion of a growth factor, improve survival rate, improve mobility to an injured part, improve proliferation rate and maintain characteristics of the stem cell, thus promoting an activation of the stem cell such that the stem cell becomes suitable for transplantation of the stem cell to a patient having a brain injury.
    Type: Application
    Filed: October 4, 2013
    Publication date: November 26, 2015
    Inventors: Oh Young Bang, Gyeong Joon Moon, Yeon Hee Cho, Suk Jae Kim, Dong Hee Kim, Soo Kyung Ryoo, Ji Hyun Lee, Ji Yoon Nam, Ji Hee Sung
  • Publication number: 20150045298
    Abstract: The present invention relates to a composition including stem cell-derived microvesicles as an active ingredient for promoting neurogenesis. The stem cell-derived microvesicles according to the present invention can promote neurogenesis and migration of nerves and also promote angiogenesis in vascular endothelial cells, and thus can be usefully used in treatment of neurological damage.
    Type: Application
    Filed: August 14, 2012
    Publication date: February 12, 2015
    Applicant: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Oh Young Bang, Gyeong Joon Moon, Yeon Hee Cho, Suk Jae Kim, Dong Hee Kim, Ji Hee Sung
  • Patent number: 8637003
    Abstract: The present invention provides a method for treating multiple system atrophy, comprising administering a therapeutically effective amount of mesenchymal stem cells (MSCs) to a human in need thereof. Preferably, the administering is performed by an intra-arterial injection of said MSCs and one or more intravenous injections of said MSCs.
    Type: Grant
    Filed: April 23, 2008
    Date of Patent: January 28, 2014
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Phil Hyu Lee, Oh Young Bang, Young Hwan Ahn
  • Publication number: 20090269311
    Abstract: The present invention provides a method for treating multiple system atrophy, comprising administering a therapeutically effective amount of mesenchymal stem cells (MSCs) to a human in need thereof. Preferably, the administering is performed by an intra-arterial injection of said MSCs and one or more intravenous injections of said MSCs.
    Type: Application
    Filed: April 23, 2008
    Publication date: October 29, 2009
    Applicant: AJOU UNIVERSITY INDUSTRY- ACADEMIC COOPERATION FOUNDATION
    Inventors: Phil Hyu Lee, Oh Young Bang, Young Hwan Ahn